Literature DB >> 15748844

Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice.

Lauren M Billings1, Salvatore Oddo, Kim N Green, James L McGaugh, Frank M LaFerla.   

Abstract

Progressive memory loss and cognitive dysfunction are the hallmark clinical features of Alzheimer's disease (AD). Identifying the molecular triggers for the onset of AD-related cognitive decline presently requires the use of suitable animal models, such as the 3xTg-AD mice, which develop both amyloid and tangle pathology. Here, we characterize the onset of learning and memory deficits in this model. We report that 2-month-old, prepathologic mice are cognitively unimpaired. The earliest cognitive impairment manifests at 4 months as a deficit in long-term retention and correlates with the accumulation of intraneuronal Abeta in the hippocampus and amygdala. Plaque or tangle pathology is not apparent at this age, suggesting that they contribute to cognitive dysfunction at later time points. Clearance of the intraneuronal Abeta pathology by immunotherapy rescues the early cognitive deficits on a hippocampal-dependent task. Reemergence of the Abeta pathology again leads to cognitive deficits. This study strongly implicates intraneuronal Abeta in the onset of cognitive dysfunction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15748844     DOI: 10.1016/j.neuron.2005.01.040

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  477 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

Review 2.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

3.  FBL2 regulates amyloid precursor protein (APP) metabolism by promoting ubiquitination-dependent APP degradation and inhibition of APP endocytosis.

Authors:  Tomomichi Watanabe; Yukiko Hikichi; Antje Willuweit; Yasushi Shintani; Takashi Horiguchi
Journal:  J Neurosci       Date:  2012-03-07       Impact factor: 6.167

4.  Nanoinjection: pronuclear DNA delivery using a charged lance.

Authors:  Quentin T Aten; Brian D Jensen; Susan Tamowski; Aubrey M Wilson; Larry L Howell; Sandra H Burnett
Journal:  Transgenic Res       Date:  2012-03-14       Impact factor: 2.788

5.  Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity.

Authors:  David X Medina; Antonella Caccamo; Salvatore Oddo
Journal:  Brain Pathol       Date:  2011-03       Impact factor: 6.508

6.  Membrane localization of beta-amyloid 1-42 in lysosomes: a possible mechanism for lysosome labilization.

Authors:  Rui-Qin Liu; Qing-Hua Zhou; Shang-Rong Ji; Qiang Zhou; Du Feng; Yi Wu; Sen-Fang Sui
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

7.  Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice.

Authors:  Davide Tampellini; Estibaliz Capetillo-Zarate; Magali Dumont; Zhenyong Huang; Fangmin Yu; Michael T Lin; Gunnar K Gouras
Journal:  J Neurosci       Date:  2010-10-27       Impact factor: 6.167

Review 8.  Anti-dementia drugs and hippocampal-dependent memory in rodents.

Authors:  Carla M Yuede; Hongxin Dong; John G Csernansky
Journal:  Behav Pharmacol       Date:  2007-09       Impact factor: 2.293

9.  Alterations in synaptic plasticity coincide with deficits in spatial working memory in presymptomatic 3xTg-AD mice.

Authors:  Jason K Clark; Matthew Furgerson; Jonathon D Crystal; Marcus Fechheimer; Ruth Furukawa; John J Wagner
Journal:  Neurobiol Learn Mem       Date:  2015-09-15       Impact factor: 2.877

10.  Presenilin PS1∆E9 disrupts mobility of secretory organelles in rat astrocytes.

Authors:  M Stenovec; S Trkov Bobnar; T Smolič; M Kreft; V Parpura; R Zorec
Journal:  Acta Physiol (Oxf)       Date:  2018-02-19       Impact factor: 6.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.